{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T18:38:30Z","timestamp":1774895910804,"version":"3.50.1"},"reference-count":25,"publisher":"Becaris Publishing Limited","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:p><jats:bold>Aim:<\/jats:bold>Psoriasis includes unpleasant symptoms such as pain. This study aimed to investigate whether clinical trials have domains related to pain in their study designs.<jats:bold>Materials and methods:<\/jats:bold>We analyzed all clinical trials about interventions for psoriasis treatment registered on ClinicalTrials.gov and the frequency of pain-related outcomes.<jats:bold>Results:<\/jats:bold>Our analysis included 1033 registered clinical trials. They had 1329 primary outcomes and 5457 secondary outcomes. The pain was used in six\u00a0(0.6%) protocols as a primary outcome and 68 (6.5%) protocols as a secondary outcome.<jats:bold>Conclusion:<\/jats:bold>Pain as an outcome was used in few registered clinical trial protocols for the treatment of psoriatic conditions. Future studies should investigate why the trialists do not include pain among primary or secondary outcomes.<\/jats:p>","DOI":"10.2217\/cer-2021-0012","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T08:46:03Z","timestamp":1623401163000},"page":"909-915","source":"Crossref","is-referenced-by-count":3,"title":["Outcome domains and measures for pain in psoriasis used in registered trials: analysis of studies on ClinicalTrials.gov"],"prefix":"10.57264","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9232-2634","authenticated-orcid":false,"given":"Ana Sanader","family":"Vucemilovic","sequence":"first","affiliation":[{"name":"Department of Dermatovenerology, University Hospital\u00a0Centre Split, Split, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Puljak","sequence":"additional","affiliation":[{"name":"Center for Evidence-Based Medicine &amp; Health Care, Catholic University of Croatia, Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"5","key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle FO","year":"2009","unstructured":"Nestle FO, Kaplan DH, Barker J. Psoriasis. N. Engl. J. Med. 361(5), 496\u2013509 (2009).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","article-title":"Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey","volume":"70","author":"Lebwohl MG","year":"2014","unstructured":"Lebwohl MG, Bachelez H, Barker J Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J. Am. Acad. Dermatol. 70(5), 871\u2013881.E30 (2014).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"9","key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199503023320907","article-title":"Treatment of psoriasis","volume":"332","author":"Greaves MW","year":"1995","unstructured":"Greaves MW, Weinstein GD. Treatment of psoriasis. N. Engl. J. Med. 332(9), 581\u2013588 (1995).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter A","year":"2008","unstructured":"Menter A, Gottlieb A, Feldman SR Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J. Am. Acad. Dermatol. 58(5), 826\u2013850 (2008).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","article-title":"Psoriasis: which therapy for which patient: focus on special populations and chronic infections","volume":"80","author":"Kaushik SB","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J. Am. Acad. Dermatol. 80(1), 43\u201353 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","article-title":"Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents","volume":"80","author":"Kaushik SB","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J. Am. Acad. Dermatol. 80(1), 27\u201340 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1365-2133.2004.06093.x","article-title":"Prevalence of symptoms experienced by patients with different clinical types of psoriasis","volume":"151","author":"Sampogna F","year":"2004","unstructured":"Sampogna F, Gisondi P, Melchi CF, Amerio P, Girolomoni G, Abeni D. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br. J. Dermatol. 151(3), 594\u2013599 (2004).","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0190-9622(97)80214-9","article-title":"The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort","volume":"36","author":"Mckenna KE","year":"1997","unstructured":"Mckenna KE, Stern RS. The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. J. Am. Acad. Dermatol. 36(3 Pt 1), 388\u2013394 (1997).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"7","key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1474-4422(11)70106-5","article-title":"Clinical features and pathophysiology of complex regional pain syndrome","volume":"10","author":"Marinus J","year":"2011","unstructured":"Marinus J, Moseley GL, Birklein F Clinical features and pathophysiology of complex regional pain syndrome. Lancet Neurol. 10(7), 637\u2013648 (2011).","journal-title":"Lancet Neurol."},{"issue":"6","key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/acr.22528","article-title":"Prevalence of chronic axial pain, inflammatory back pain, and spondyloarthritis in diagnosed psoriasis","volume":"67","author":"Thom N","year":"2015","unstructured":"Thom N, Ritchlin CT, Zhang X, Reveille J, Weisman MH. Prevalence of chronic axial pain, inflammatory back pain, and spondyloarthritis in diagnosed psoriasis. Arthritis Care Res. (Hoboken) 67(6), 829\u2013835 (2015).","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"10","key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"pii:13030\/qt1x1","DOI":"10.5070\/D32110028943","article-title":"Increased severity of itching, pain, and scaling in psoriasis patients is associated with increased disease severity, reduced quality of life, and reduced work productivity","volume":"21","author":"Korman NJ","year":"2015","unstructured":"Korman NJ, Zhao Y, Pike J, Roberts J, Sullivan E. Increased severity of itching, pain, and scaling in psoriasis patients is associated with increased disease severity, reduced quality of life, and reduced work productivity. Dermatol. Online J. 21(10), pii:13030\/qt1x16v3dg (2015).","journal-title":"Dermatol. Online J."},{"issue":"7503","key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature13199","article-title":"Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation","volume":"510","author":"Riol-Blanco L","year":"2014","unstructured":"Riol-Blanco L, Ordovas-Montanes J, Perro M Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation. Nature 510(7503), 157\u2013161 (2014).","journal-title":"Nature"},{"issue":"1","key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1468-3083.2011.04000.x","article-title":"Skin pain and skin discomfort is associated with quality of life in patients with psoriasis","volume":"26","author":"Ljosaa TM","year":"2012","unstructured":"Ljosaa TM, Mork C, Stubhaug A, Moum T, Wahl AK. Skin pain and skin discomfort is associated with quality of life in patients with psoriasis. J. Eur. Acad. Dermatol. Venereol. 26(1), 29\u201335 (2012).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"10","key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/jamadermatol.2018.1165","article-title":"Identifying a core domain set to assess psoriasis in clinical trials","volume":"154","author":"Callis Duffin K","year":"2018","unstructured":"Callis Duffin K, Merola JF, Christensen R Identifying a core domain set to assess psoriasis in clinical trials. JAMA Dermatol. 154(10), 1137\u20131144 (2018).","journal-title":"JAMA Dermatol."},{"issue":"4","key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40257-020-00521-3","article-title":"Treatment goals in psoriasis: which outcomes matter most?","volume":"21","author":"Svoboda SA","year":"2020","unstructured":"Svoboda SA, Ghamrawi RI, Owusu DA, Feldman SR. Treatment goals in psoriasis: which outcomes matter most? Am. J. Clin. Dermatol. 21(4), 505\u2013511 (2020).","journal-title":"Am. J. Clin. Dermatol."},{"issue":"1","key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40257-015-0169-x","article-title":"US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey","volume":"17","author":"Lebwohl MG","year":"2016","unstructured":"Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Am. J. Clin. Dermatol. 17(1), 87\u201397 (2016).","journal-title":"Am. J. Clin. Dermatol."},{"issue":"3","key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/bjd.15831","article-title":"Reporting of outcomes in randomized controlled trials on nail psoriasis: a systematic review","volume":"178","author":"Busard CI","year":"2018","unstructured":"Busard CI, Nolte JYC, Pasch MC, Spuls PI. Reporting of outcomes in randomized controlled trials on nail psoriasis: a systematic review. Br. J. Dermatol. 178(3), 640\u2013649 (2018).","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s11136-015-1136-y","article-title":"Patient-relevant needs and treatment goals in nail psoriasis","volume":"25","author":"Blome C","year":"2016","unstructured":"Blome C, Costanzo A, Dauden E Patient-relevant needs and treatment goals in nail psoriasis. Qual. Life Res. 25(5), 1179\u20131188 (2016).","journal-title":"Qual. Life Res."},{"issue":"9","key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/1756-185X.12505","article-title":"Sleep quality in patients with psoriatic arthritis","volume":"20","author":"Gezer O","year":"2017","unstructured":"Gezer O, Batmaz I, Sariyildiz MA Sleep quality in patients with psoriatic arthritis. Int. J. Rheum. Dis. 20(9), 1212\u20131218 (2017).","journal-title":"Int. J. Rheum. Dis."},{"issue":"1","key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaad.2009.07.003","article-title":"Factors affecting sleep quality in patients with psoriasis","volume":"63","author":"Gowda S","year":"2010","unstructured":"Gowda S, Goldblum OM, Mccall WV, Feldman SR. Factors affecting sleep quality in patients with psoriasis. J. Am. Acad. Dermatol. 63(1), 114\u2013123 (2010).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1468-3083.2009.03344.x","article-title":"Development and validation of nail psoriasis quality of life scale (NPQ10)","volume":"24","author":"Ortonne JP","year":"2010","unstructured":"Ortonne JP, Baran R, Corvest M, Schmitt C, Voisard JJ, Taieb C. Development and validation of nail psoriasis quality of life scale (NPQ10). J. Eur. Acad. Dermatol. Venereol. 24(1), 22\u201327 (2010).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"6","key":"e_1_3_4_24_2","first-page":"803","article-title":"Scalpdex: a quality-of-life instrument for scalp dermatitis","volume":"138","author":"Chen SC","year":"2002","unstructured":"Chen SC, Yeung J, Chren MM. Scalpdex: a quality-of-life instrument for scalp dermatitis. Arch. Dermatol. 138(6), 803\u2013807 (2002).","journal-title":"Arch. Dermatol."},{"key":"e_1_3_4_25_2","first-page":"41","article-title":"The impact of genital psoriasis on quality of life: a systematic review","volume":"8","author":"Yang EJ","year":"2018","unstructured":"Yang EJ, Beck KM, Sanchez IM, Koo J, Liao W. The impact of genital psoriasis on quality of life: a systematic review. Psoriasis (Auckl.) 8, 41\u201347 (2018).","journal-title":"Psoriasis (Auckl.)"},{"issue":"6","key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"e031461","DOI":"10.1136\/bmjopen-2019-031461","article-title":"Pain associated with psoriasis: systematic scoping review protocol","volume":"10","author":"Sanader Vucemilovic A","year":"2020","unstructured":"Sanader Vucemilovic A, Nujic D, Puljak L. Pain associated with psoriasis: systematic scoping review protocol. BMJ Open 10(6), e031461 (2020).","journal-title":"BMJ Open"},{"issue":"1","key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","article-title":"Core outcome measures for chronic pain clinical trials: IMMPACT recommendations","volume":"113","author":"Dworkin RH","year":"2005","unstructured":"Dworkin RH, Turk DC, Farrar JT Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113(1\u20132), 9\u201319 (2005).","journal-title":"Pain"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2021-0012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T20:04:00Z","timestamp":1699128240000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2021-0012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.2217\/cer-2021-0012"],"URL":"https:\/\/doi.org\/10.2217\/cer-2021-0012","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}